bioRxivSystems BiologyPreprint
Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance
Kate BridgesiD, Gabriela A. PizzurroiD, Alev BaysoyiD, Janani P. BaskaraniD, Ziyan Zoe XuiD, Varsha MathewiD, Victoria TrippleiD, Michael LaPorte, Koonam ParkiD, William DamskyiD, Harriet M. KlugeriD, Rong FaniD, Susan M. KaechiD, Marcus BosenbergiD, Kathryn Miller‐JenseniD
Abstract
Effective cancer immunotherapies restore anti-tumor immunity by rewiring cell-cell communication. Treatment-induced changes in communication can be inferred from single-cell RNA-sequencing (scRNA-seq) data, but current methods do not effectively manage heterogeneity within cell types. Here we developed a computational approach to efficiently analyze scRNA-seq-derived, single-cell-resolved cell-cell interactomes, which we applied to determine how agonistic CD40 (CD40ag) alters immune cell crosstalk alone, across tumor models, and in combination with immune checkpoint blockade (ICB). Our analyses suggested that CD40ag improves responses to ICB by targeting both immuno-stimulatory and immunosuppressive macrophage subsets communicating with T cells, and we experimentally validated a spatial basis for these subsets with immunofluorescence and spatial transcriptomics. Moreover, treatment with CD40ag and ICB established coordinated myeloid-T cell interaction hubs that are critical for reestablishing antitumor immunity. Our work advances the biological significance of hypotheses generated from scRNA-seq-derived cell-cell interactomes and supports the clinical translation of myeloid-targeted therapies for ICB-resistant tumors.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Integrated single-cell and spatial analysis identifies context-dependent myeloid-T cell interactions in head and neck cancer immune checkpoint blockade response
Athena E. Golfinos, Taja Ložar, … Huy Q. Dinh·bioRxiv·Mar 24, 2025
- OX40 agonism enhances efficacy of PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum
G. Beyrend, T. C. van der Sluis, … R. Arens·bioRxiv·Dec 24, 2021
- A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanoma
J. Pozniak, D. Pedri, … J.-C. Marine·bioRxiv·Aug 11, 2022
- Cancer cells communicate with macrophages to prevent T cell activation during development of cell cycle therapy resistance
J. I. Griffiths, P. A. Cosgrove, … A. H. Bild·bioRxiv·Sep 14, 2022
- Innate Immune Remodeling Drives Therapy Resistance via Macrophage-NK Cell Crosstalk.
Chia‐Hsin Hsu, Keng‐Jung Lee, … Andrew C. White·bioRxiv·Jul 22, 2025
- Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy
J. I. Griffiths, P. Wallet, … A. H. Bild·Proceedings of the National Academy of SciencesPeer-reviewed·Jun 22, 2020